RxDoctor Payments Data

Katie Ortman, PA

Physician Assistant · Brookfield, WINPI 1285267732

Payments from drug & device makers

$2,961in general payments, 2019–2025

Across 123 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$393
  • AstraZeneca$374
  • Novartis$289
  • E.r. Squibb & Sons, L.L.C.$240
  • Pfizer$231
  • Alnylam Pharmaceuticals Inc.$228
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,961100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,961 in reported general payments places this provider in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$27,905
Medicare patients
199
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$182,471
FarxigaDapagliflozin Propanediol51$60,359
EntrestoSacubitril/Valsartan27$38,517
JardianceEmpagliflozin22$28,722
XareltoRivaroxaban16$16,438
BrilintaTicagrelor16$11,457
Metoprolol Succinate189$3,554
Atorvastatin Calcium197$2,002
Bumetanide57$1,789
Losartan Potassium124$1,284
Rosuvastatin Calcium74$1,107
Spironolactone143$871
ClopidogrelClopidogrel Bisulfate93$866
Ezetimibe41$814
Furosemide127$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$231$182,471157 claims
AstraZenecaFarxiga, Brilinta$374$71,81667 claims
NovartisEntresto$289$38,51727 claims
Boehringer IngelheimJardiance$15$28,72222 claims
Johnson & JohnsonXarelto$166$16,43816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →